At a glance
- Originator Merck Frosst
- Class Acetic acids; Antiallergics
- Mechanism of Action Leukotriene inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Respiratory tract disorders
Most Recent Events
- 20 Aug 1996 No-Development-Reported for Respiratory tract disorders in Canada (Unknown route)